Acute myeloid Leukemia (AML) Azacitidine improves Overall Survival of elderly Patients with more than 30% Bone Marrow Blasts

被引：0
|
作者：
Schoellmann, Claudia
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 05期
关键词：
CANCER;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [1] AZACITIDINE (AZA) IMPROVES OVERALL SURVIVAL (OS) IN WHO ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS WITH LOW BONE MARROW BLAST COUNTS
    Fenaux, P. F.
    Silverman, L. R.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    Santini, V.
    Gattermann, N.
    Sanz, G.
    Seymour, J. F.
    Gore, S. D.
    Dombret, H.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 430 - 431
  • [2] Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study
    Doehner, Hartmut
    Seymour, John F.
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Lang, Jun Ho
    Cavenagh, James D.
    Kumar, Rajat
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Stephen
    Lucy, Lela M.
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2014, 124 (21)
  • [3] Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts
    van der Helm, L. H.
    Veeger, N. J. G. M.
    van Marwijk Kooy, M.
    Beeker, A.
    de Weerdt, O.
    de Groot, M.
    Alhan, C.
    Hoogendoorn, M.
    Laterveer, L.
    van de Loosdrecht, A. A.
    Koedam, J.
    Vellenga, E.
    Huls, G.
    LEUKEMIA RESEARCH, 2013, 37 (08) : 877 - 882
  • [4] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Gattermann, Norbert
    Germing, Ulrich
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven
    Seymour, John F.
    Dombret, Herve
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 562 - 569
  • [5] AZACITIDINE IMPROVES SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES WITH 20-30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETIC CATEGOR
    Falantes, J. F.
    Calderon, C.
    Marquez-Malaver, F. J.
    Carrillo, E.
    Bernal, R.
    Morales, R.
    Parody, R.
    Gonzalez, J.
    Montero, I.
    Martino, M. L.
    Espigado, I.
    Perez-Simon, J. A.
    HAEMATOLOGICA, 2014, 99 : 614 - 614
  • [6] Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts
    Maurillo, Luca
    Buccisano, Francesco
    Del Principe, Maria Ilaria
    Sarlo, Chiara
    Di Caprio, Luigi
    Ditto, Concetta
    Giannotti, Federica
    Nasso, Daniela
    Ceresoli, Eleonora
    Postorino, Massimiliano
    Refrigeri, Marco
    Amadori, Sergio
    Venditti, Adriano
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2013, 5 (01)
  • [7] Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia
    Font P.
    Advances in Therapy, 2011, 28 (Suppl 3) : 1 - 9
  • [8] AZACITIDINE FOR THE TREATMENT OF ADULT PATIENTS (AGE 65 OR OLDER) WITH ACUTE MYELOID LEUKEMIA AND >30% BONE MARROW BLASTS IN SPAIN: BUDGET IMPACT ANALYSIS
    Caloto, T.
    Dias Ferreira, C.
    Rafel, M.
    Rovira, G.
    VALUE IN HEALTH, 2016, 19 (07) : A581 - A581
  • [9] IMPACT OF COMORBIDITIES ON OVERALL SURVIVAL IN THE ELDERLY WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA TREATED BY AZACITIDINE
    Brechemier, D.
    Bertoli, S.
    Comont, T.
    Balardy, L.
    Recher, C.
    Lauwers-Cances, V.
    Beyne-Rauzy, O.
    LEUKEMIA RESEARCH, 2015, 39 : S47 - S48
  • [10] OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH > 30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY
    Doehner, H.
    Seymour, J. F.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Cavenagh, J. D.
    Kumar, R.
    Schuh, A. C.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    Bernal del Castillo, T.
    Al-Ali, H. K.
    Martinelli, G.
    Falantes, J.
    Nopenney, R.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L. M.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2015, 39 : S48 - S49
12345